Drug Trial Radar · NCT07480356
Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
284
Planned (sponsor's estimate)
Start
May 29, 2026
Primary completion
Apr 2028
Study completion Nov 2032
Sponsor
- Lead sponsor
- Protara TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if TARA-002 can treat high-grade non-muscle invasive bladder cancer (NMIBC) in BCG-naïve adults 18 years of age or older. The main questions it aims to answer are: * Can the study drug help participants with this type of cancer? * Is the study drug safe? * What are the side effects of the study drug? Researchers will compare TARA-002 to chemotherapy to see if TARA-002 works to treat NMIBC.
Conditions
- Bladder (Urothelial, Transitional Cell) Cancer
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
TARA-002Drug
Participants will receive 6 weekly instillations of TARA-002. Participants confirmed to have a CR at Week 12 will enter the maintenance treatment period and will receive 3 additional weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25. Participants who are eligible for reinduction at Week 12 will receive 6 additional weekly instillations of TARA-002. Participants who undergo reinduction and are confirmed to have a CR at Week 24 will enter the maintenance regimen treatment period and will receive 3 weekly instillations of TARA-002 every 3 months up to Month 19, and then 3 weekly doses at Month 25.
Investigator's Choice of Intravesical ChemotherapyDrug
Participants will receive 6 weekly instillations of Investigator's choice of intravesical chemotherapy. Participants confirmed to have a CR at Week 12 will enter the maintenance regimen treatment period and will receive one intravesical instillation of Investigator's choice of intravesical chemotherapy every 1 month up to Month 25.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of high-grade complete responseTime frame: Month 6
Locations
11 sites in 2 countries. Site status is shown where the registry gives one.
East Valley Urology Center of Arizona
Queen Creek, Arizona · Recruiting
Arkansas Urology
Little Rock, Arkansas · Recruiting
Michael Oefelein Clinical Trials
Bakersfield, California · Recruiting
Urology of Greater Atlanta - Sandy Springs
Atlanta, Georgia · Recruiting
Renown Regional Medical Center
St Louis, Missouri · Recruiting
START - Carolinas
Myrtle Beach, South Carolina · Recruiting
Urology Partners of North Texas
Arlington, Texas · Recruiting
Urology Austin, LLC
Austin, Texas · Recruiting
Houston Metro Urology
Houston, Texas · Recruiting
Arenia - Ivano-Frankivsk
Ivano-Frankivsk, Ukraine · Recruiting
Arensia Kapitanivka - PPDS
Kapitanivka, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.